期刊文献+

胃结肠癌患者血清TK1的分布及诊断价值 被引量:2

The distribution and diagnostic value evaluation of serum thymidine kinase 1 in gastricand colonic cancer patients
暂未订购
导出
摘要 目的探讨胃结肠癌患者血清胸苷激酶1(Thymidine kinase 1,TK1)的分布情况和诊断价值。方法免疫印迹增强化学发光法检测70例胃结肠癌患者(研究组)、48例健康体检者(对照组)的血清TK1值,分析分布形态,计算基于参考值的阳性率,比较集中趋势,ROC曲线分析诊断价值。结果研究组与对照组的偏度系数分别为4.975、0.836,研究组的阳性率高于对照组(37.14%VS4.17%,P〈0.01),研究组的中位数大于对照组(1.56VS0.91,P〈0.01),ROC曲线下面积为0.7987,临界值为2.025pmol/L时,阳性似然比为最大值17.83,灵敏度、特异度分别为37.14%、97.92%。结论胃结肠癌患者的TK1值呈正偏分布,可能预示癌细胞和宿主细胞的增殖状态差异,其阳性率和中位数均高于正常对照组,参考值为2.025pmol/L的诊断价值较高。 Objective To explore the distribution charateristics and evaluate the diagnostic ralue of serum thymidine kinase 1 (TK1) in the gastric and colonic cancer patients. Methods 70 cases of ;astric and colonic cancer patients(observation group) ,48 cases of healthy people(control group) under- ~ent serum TK1 detection using an ECL dot blot assay, TKI's statistical distribution, positive rate and ',entral tendency were analyzed and compared between two groups, its clinical diagnostic value was evalu- ated using receiver operating characteristic (ROC) curve. Results The coefficients of skewness were 4. t75,0.836 in observation group and control group respectively, the positve rate in observation group was ignificantly higher than that in control group(37.14% vs 4.17%, P〈 0.01), the TK1 median in observa- ion group was also significantly higher than that in control group(1.56 vs 0.91, P〈 0.01), ROC analysis howed that the area under curve (AUC) was 0.7987. When the cutoff value was 2.025 pmol/L, the positive ikelihood ratio was the biggest(17.83), then the sensitivity and specificity were 37.14% ,97.92% respectively. Conclusions TK1 values in gastric and colonic cancer patients are not normal distribution, its outliers aay imply the proliferation difference of both cancer and non-cancer cells, its positive rate and median are ignificantly higher than those of healthy people, its diagnostic value is best when cutoff value is 2.025 ,mol/L.
出处 《国际医药卫生导报》 2012年第20期2939-2942,共4页 International Medicine and Health Guidance News
基金 2011年度安徽省博士后研究人员科研活动经费资助项目 安徽高校省级自然科学研究项目(KJ20122180)
关键词 胸苷激酶1(TK10) 胃癌 结肠癌 诊断 Thymidine kinase 1 Gastric cancer Colon cancer Diagnosis
  • 相关文献

参考文献11

二级参考文献76

共引文献432

同被引文献22

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1379
  • 2Zhang F, Li H, Pendleton AR, et al. Thymidine kinase 1 immunoas- say:a potential marker for breast cancer [ J ]. Cancer Detect Prey, 2001,25(1) :8 -15.
  • 3Plotti F, Nelaj E, Sansone M, et al. Sexual function after modified radical hysterectomy( Piver II/Type B) vs. classic radical hysterecto- my( Piver III/Type C2 )for early stage cervical cancer. A prospective study[J]. J Sex Med,2012,9(3) :909 -917.
  • 4Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1- mediated pathway [ J ]. Mol Cell Biol,2004,24 ( 2 ) : 514 - 526.
  • 5Huang S, Lin J, Guo N, et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression [ J ]. Asian Pae J Cancer Prey,2011,12(2) :497 -505.
  • 6Chen Y,Ying M,Chen Y,et al. Serum thymidine kinase ! correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings[ J]. Int J Clin Onco1,2010,15 (4) :359 - 368.
  • 7Sauter G, Algaba F, Amin M, et al. Tumour of urinary system: non-invasive urothelial neoplasia[ M ]//In Eble JN, Sauter G, Epstein JI, et al. WHO Classification of Classification of Tumour of urinary system and male genital organs. Lyon: LARCC Press,2004.
  • 8Sobin LH, Gospodariwicz M, Wittekind C. TNM classification of malignant tumours. UICC International Union Against Cancer [ M ]. 7th ed. Wiley-Blackwell,2009 : 262 - 265.
  • 9Sharif H,van Euler H,Westberg S,et al. A sensitive and kineti- cally defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lympho- ma[J]. Vet J,2012,194(1):40-47.
  • 10Chen Y, Ying M, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1 247 cancer patients in routine clinical settings [ J ]. Int J Clin Oncol, 2010, 15 ( 4 ) : 359 - 368.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部